Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
azacitidine + tislelizumab
- Development stage
- Phase 2
- Lead developer
- BeiGene
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous, Subcutaneous
01
Overview
Azacitidine + tislelizumab is an investigational combination therapy consisting of azacitidine, a DNA methyltransferase inhibitor (epigenetic modulator), and tislelizumab, a monoclonal antibody targeting programmed cell death protein 1 (PD-1). Azacitidine works by inhibiting DNA methylation, leading to reactivation of tumor suppressor genes and increased cancer cell death. Tislelizumab is an immune checkpoint inhibitor that blocks PD-1 on T cells, preventing cancer cells from evading immune detection and destruction. This combination aims to enhance antitumor immunity by both modifying the tumor microenvironment with azacitidine and unleashing immune responses with PD-1 blockade via tislelizumab. The combination is under clinical investigation for various advanced solid tumors and hematologic malignancies.
- Other names
- azacitidine + tislelizumabaza + tislelizumab
02
Targets
DNMT1 (DNA (cytosine-5)-methyltransferase 1)DNMT3A (DNA methyltransferase 3 alpha)DNMT3B (DNA (cytosine-5)-methyltransferase 3B)PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on azacitidine + tislelizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on azacitidine + tislelizumab.